GlassScriptPhysician profile
Nicole E Barberis
NPI 1487093514
$351,058.50
in general payments reported to CMS, 2019-2025
34 companies · $125K in 2025
The $125K reported for 2025 was more than what 98% of Allergy & Immunology providers received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,926 · 2020: $9,238 · 2021: $17K · 2022: $35K · 2023: $82K · 2024: $80K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $162K · Consulting Fee: $79K · Travel and Lodging: $32K · Food and Beverage: $14K · Education: $62.08.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $162,312.12 |
| Consulting Fee | $78,984.75 |
| Travel and Lodging | $32,426.91 |
| Food and Beverage | $13,500.52 |
| Education | $62.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $235,738.82 | 2019-2025 | |
| Regeneron Healthcare Solutions, INC. | $82,410.73 | 2019-2025 | Dupixent |
| Astrazeneca Pharmaceuticals LP | $11,367.32 | 2019-2025 | Fasenra, Tezspire, Breztri |
| Novartis Pharmaceuticals Corporation | $4,953.38 | 2020-2025 | |
| Kaleo, INC. | $4,014.86 | 2020-2024 | Auvi-Q |
| Sanofi US Services INC. | $2,660.00 | 2025 | |
| Grifols USA, LLC | $1,965.73 | 2019-2025 | Xembify, Prolastin-C Liquid |
| Genentech USA, INC. | $1,868.18 | 2019-2025 | Xolair |
| Grifols Shared Services North America, INC. | $1,327.50 | 2025 | Xembify |
| Arcutis Biotherapeutics, INC. | $1,100.00 | 2025 | Zoryve |
| Glaxosmithkline, LLC. | $841.41 | 2019-2025 | Nucala, Trelegy Ellipta |
| Takeda Pharmaceuticals U.S.A., INC. | $476.78 | 2020-2025 | Cuvitru, Hyqvia, Takhzyro |
| Alk-Abello, INC | $390.26 | 2019-2021 | |
| Pharming Healthcare, INC. | $275.91 | 2020-2025 | Ruconest |
| Blueprint Medicines Corporation | $231.27 | 2023-2025 | Ayvakit |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $203.86 | 2022-2024 | Tezspire |
| Lilly USA, LLC | $165.44 | 2023-2025 | Ebglyss, Olumiant |
| Genentech, INC. | $145.98 | 2025 | Xolair |
| Organon LLC | $128.60 | 2025 | Vtama |
| Pfizer INC. | $122.95 | 2019 | |
| Sanofi-Aventis U.S. LLC | $121.95 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $93.37 | 2021 | |
| Biocryst US Sales Co., LLC | $84.81 | 2024-2025 | Orladeyo |
| Incyte Corporation | $80.37 | 2024-2025 | Opzelura |
| Optinose US, INC. | $76.31 | 2022-2024 | |
| Csl Behring | $45.92 | 2020-2025 | Andembry |
| Galderma Laboratories, L.P. | $28.01 | 2025 | Nemluvio |
| Abbvie INC. | $26.43 | 2023 | Rinvoq |
| Shire North American Group INC | $25.67 | 2019 | |
| Ars Pharmaceuticals Operations, INC. | $24.47 | 2025 | Neffy |
| Dermavant Sciences, INC. | $18.41 | 2024 | Vtama |
| Cycle Pharmaceuticals INC | $18.14 | 2025 | Sajazir |
| Ionis Pharmaceuticals, INC. | $14.68 | 2025 | Dawnzera |
| Teva Pharmaceuticals USA, INC. | $10.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Barberis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.